Garry Neil
2021
In 2021, Garry Neil earned a total compensation of $1.2M as Chief Executive Officer, President, Chairman of the Board and principal executive officer at Avalo Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $239,587 |
|---|---|
| Option Awards | $571,484 |
| Salary | $423,000 |
| Total | $1,234,071 |
Neil received $571.5K in option awards, accounting for 46% of the total pay in 2021.
Neil also received $239.6K in non-equity incentive plan and $423K in salary.
Rankings
In 2021, Garry Neil's compensation ranked 8,017th out of 12,406 executives tracked by ExecPay. In other words, Neil earned more than 35.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,017 out of 12,406 | 35th |
Division Manufacturing | 3,546 out of 5,492 | 35th |
Major group Chemicals And Allied Products | 1,577 out of 2,368 | 33rd |
Industry group Drugs | 1,402 out of 2,089 | 33rd |
Industry Pharmaceutical Preparations | 1,039 out of 1,536 | 32nd |
Source: SEC filing on October 19, 2023.
Neil's colleagues
We found four more compensation records of executives who worked with Garry Neil at Avalo Therapeutics in 2021.